[CAS NO. 298197-04-3] Fatostatin (125B11) HBr

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [298197-04-3]

Catalog

SLK-S8284

Brand

Selleck

CAS

298197-04-3

DESCRIPTION [298197-04-3]

Overview

MDL	MFCD02376000
Molecular Weight	375.33
Molecular Formula	C18H18N2S·HBr
SMILES	CC1=CC=C(C2=CSC(C3=CC(CCC)=NC=C3)=N2)C=C1.[H]Br

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Concentration Volume Mass	1 mg	5 mg	10 mg
1 mM	2.6643 mL	13.3216 mL	26.6432 mL
5 mM	0.5329 mL	2.6643 mL	5.3286 mL
10 mM	0.2664 mL	1.3322 mL	2.6643 mL
50 mM	0.0533 mL	0.2664 mL	0.5329 mL

Description

Fatostatin HBr (Fatostatin A, 125B11) is an inhibitor of . It impairs the activation of SREBP-1 and SREBP-2.

Targets

SREBPs ^[1]

In vitro

Fatostatin inhibits the insulin-induced adipogenesis of 3T3-L1 cells and the serum-independent growth of human androgen-independent prostate cancer (DU145) cells. Fatostatin blocks the activation of SREBPs in cells in tissue culture. Fatostatin suppresses cell proliferation and anchorage-independent colony formation in both androgen-responsive LNCaP and androgen-insensitive C4-2B prostate cancer cells. Fatostatin also reduced in vitro invasion and migration in both cell lines. Further, fatostatin causes G2/M cell cycle arrest and induces apoptosis by increasing caspase-3/7 activity and the cleavages of caspase-3 and PARP.

In vivo

Fatostatin blocks increases in body weight, blood glucose, and hepatic fat accumulation in obese ob/ob mice, even under uncontrolled food intake. Fatostatin significantly inhibits subcutaneous C4-2B tumor growth and markedly decreases serum PSA level compared to the control group.

References

[1] Kamisuki S, et al. Chem Biol. 2009, 16(8):882-92.
[2] Li X, et al. Mol Cancer Ther. 2014, 13(4):855-66.